AbSci Revenue and Competitors

Claim your profile



Growjo Ranking



Estimated Revenue & Valuation

  • AbSci's estimated annual revenue is currently $6.1M per year.(i)
  • AbSci's estimated revenue per employee is $22,362
  • AbSci's total funding is $237.9M.
  • AbSci's current valuation is $614.8M. (January 2022)

Employee Data

  • AbSci has 271 Employees.(i)
  • AbSci grew their employee count by 28% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation

AbSci is a global leader in biomanufacturing technologies. The companyᅢᄁ¬ツᆲ¬トᄁs SoluProᅢᄁ¬ダᅡᄁ expression platform achieves ultra-high yields of soluble and active protein products and enables ultra-high efficiency purification processes. AbSciᅢᄁ¬ツᆲ¬トᄁs unique approach accelerates drug discovery timelines, increases manufacturing efficiencies, and drastically reduces costs for the biopharmaceutical industry. We are a fearless, intellectually energetic team of scientists continually defining the future of drug discovery and manufacturing for the biopharmaceutical industry. We welcome passionate, imaginative and accomplished scientists who are risk takers, keen to experiment, collaborate and create extraordinary drug discovery and manufacturing tools to disrupt and transform how life-changing biologics are made.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





AbSci News

2022-04-19 - Absci Co. (NASDAQ:ABSI) Sees Significant Increase in Short ...

Absci logo Absci Co. (NASDAQ:ABSI – Get Rating) was the recipient of a large increase in short interest during the month of March.

2022-03-22 - Absci Develops Groundbreaking Machine Learning Models ...

Absci to present in-silico drug discovery technology at NVIDIA GTC. Breakthrough ML achievements highlight the viability of the...

2022-03-22 - Vancouver's Absci touts value of artificial intelligence

Vancouver-based Absci presented its newest machine learning models this week, displaying a computer-generated model that can predict — with...

2021-07-22 - How Sean McClain founded Absci at just 22 — and now leads a newly public biotech worth nearly $2B

Absci CEO and founder Sean McClain rings the closing bell on the NASDAQ on Thursday with his team as the Vancouver, Wash.-based biotech company went public. (Absci Photo) Biotech CEOs tend to have advanced degrees and multiple academic credentials under their belt. But Sean McClain started Absc ...

2021-06-30 - Vancouver, Wash. biotech company Absci files to go public

Absci CEO and founder Sean McClain. (Absci Photo) Absci, a Vancouver, Wash.-based company developing technologies to accelerate the process of drug discovery, announced today that it plans to go public via an IPO. The company’s platform is built to design and generate protein-based drug candida ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding